Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: nakamichi s. Target Oncol. 2024 May;19(3):423-433. doi: 10.1007/s11523-024-01048-x. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613731 Free PMC article.
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, Naoki K, Kobayashi N, Shukuya T, Shimokawa T, Ishihara M, Wakui H, Hosomi Y, Tanaka H, Saito H, Hosokawa S, Takiguchi Y, Kasai T, Nokihara H, Morita R, Aono H, Furuya N, Okamoto H. Nakamichi S, et al. Clin Lung Cancer. 2024 Jan;25(1):85-90. doi: 10.1016/j.cllc.2023.09.006. Epub 2023 Oct 4. Clin Lung Cancer. 2024. PMID: 37981477 Clinical Trial.
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S, Kubota K, Misumi T, Kondo T, Murakami S, Shiraishi Y, Imai H, Harada D, Isobe K, Itani H, Takata S, Wakui H, Misumi Y, Ikeda S, Asao T, Furuya N, Hosokawa S, Kobayashi Y, Takiguchi Y, Okamoto H. Nakamichi S, et al. Clin Cancer Res. 2024 Mar 15;30(6):1104-1110. doi: 10.1158/1078-0432.CCR-23-2568. Clin Cancer Res. 2024. PMID: 38165684 Free PMC article. Clinical Trial.
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K, Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K, Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic Oncology Research Group (TORG). Fukui T, et al. Among authors: nakamichi s. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548-6. doi: 10.1016/j.jtho.2024.12.027. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755169
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma.
Takahashi A, Noro R, Takano N, Hisakane K, Takahashi S, Fukuizumi A, Omori M, Sugano T, Takeuchi S, Nakamichi S, Miyanaga A, Minegishi Y, Kubota K, Seike M, Gemma A. Takahashi A, et al. Among authors: nakamichi s. Mol Clin Oncol. 2022 Apr;16(4):87. doi: 10.3892/mco.2022.2520. Epub 2022 Feb 21. Mol Clin Oncol. 2022. PMID: 35251638 Free PMC article.
103 results